+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Pneumococcal Vaccine Market Size, Share & Trends Analysis Report by Vaccine Type, Product (Prevnar 13, VAXNEUVANCE, PNEUMOSIL), End-use (Public Sector, Private Sector), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 125 Pages
  • May 2024
  • Region: Global
  • Grand View Research
  • ID: 5976577
Description Jump to:
The global pneumococcal vaccine market size is anticipated to reach USD 12.19 billion by 2030, registering a CAGR of 6.21% from 2024 to 2030. The market is primarily driven by the increasing prevalence of target diseases. Pneumococcus is the main cause of invasive disease, pneumonia, and upper respiratory tract infection and can lead to severe sequelae such as deafness, paralysis, intellectual disability, and other serious complications. For instance, in September 2023, the World Health Organization (WHO) estimated that Streptococcus pneumoniae is responsible for over 300,000 deaths annually among children under the age of 5 worldwide. The majority of these fatalities occur in developing nations. Globally, S. pneumoniae is the primary cause of pneumonia-related deaths, surpassing all other causes combined. The highest number of deaths due to this bacterium is observed in countries located in Africa and Asia.

Increasing government awareness programs regarding pneumonia immunization fuels the market growth. For instance, in September 2023, a survey conducted in September and October 2022 found that there's a need to extend the recommendations for the new 20-valent pneumococcal conjugate vaccine (PCV20) to adults who previously received the 13-valent pneumococcal conjugate vaccine (PCV13). The survey showed that healthcare providers need to be more aware of and implement pneumococcal vaccination recommendations better. After considering these findings, the Advisory Committee on Immunization Practices (ACIP) agreed to update the recommendations in late October 2022.

Moreover, product launches by key players is contributing to market growth. For instance, In October 2022, Merck & Co., Inc. received the European Commission’s (EC) approval for its Vaxneuvance, a pneumococcal vaccine. The approval allows product marketing in 27 European Union (EU) member states and Iceland, Norway, & Lichtenstein. Moreover, in September 2021, Minhai Biotechnology Co. Ltd. received approval from the National Medical Products Administration, China, for its 13-valent vaccine.

Growing R&D for developing novel vaccines boosting the growth of the market. In March 2024, SK Bioscience's announced expansion of its L House vaccine manufacturing facility in South Korea indicates a proactive approach to enhancing vaccine production capacity. This expansion, driven by the joint development of the pneumococcal conjugate vaccine candidate GBP410 with Sanofi, follows positive Phase 2 clinical trial results. SK Bioscience plans to conduct a global Phase 3 clinical trial in 2027, demonstrating a commitment to collaboration and global vaccine development.

Pneumococcal Vaccine Market Report Highlights

  • Based on type, Pneumococcal Conjugate Vaccine (PCV) segment led the market and is anticipated to grow at the fastest growth over the forecast period. PCV helps protect against pneumococcal disease, a leading cause of death among children under 5 years old
  • Based on product, Prevnar 13 dominated the market and is expected to grow significantly during the forecast period. The vaccines under the Prevnar brand include Prevnar 13 and Prevnar 20. These are pneumococcal conjugate vaccines (PCVs) designed to protect against pneumococcal disease
  • Based on end-use, the public sector led the market and is anticipated to grow at the fastest CAGR over the forecast period. The dominance of the public sector in the end use of pneumococcal vaccines, including hospitals, clinics, and healthcare facilities, can be attributed to several factors. These factors include the high prevalence of diseases, government initiatives to increase vaccination coverage
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vaccine Type
1.2.2. Product
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.5.1. Data for Primary Interviews in North America
1.4.5.2. Data for Primary Interviews in Europe
1.4.5.3. Data for Primary Interviews in Asia-Pacific
1.4.5.4. Data for Primary Interviews in Latin America
1.4.5.5. Data for Primary Interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis (Model 1)
1.7.2. Approach 1: Commodity Flow Approach
1.7.3. Volume Price Analysis (Model 2)
1.7.4. Approach 2: Volume Price Analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Vaccine Type and Product Outlook
2.2.2. End Use Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights
Chapter 3. Pneumococcal Vaccine Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Target Disease
3.2.1.2. Rising Awareness and Favorable Government Initiatives
3.2.1.3. Growing R&d for Developing Novel Vaccines
3.2.2. Market Restraint Analysis
3.2.2.1. Supply Chain and Vaccine Shortage Challenges
3.2.2.2. Vaccine Hesitancy and Public Awareness
3.3. Pneumococcal Vaccine Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
3.3.3. Pricing Analysis
3.3.4. Volume Analysis (Instruments)
Chapter 4. Pneumococcal Vaccine Market: Vaccine Type Estimates & Trend Analysis
4.1. Global Pneumococcal Vaccine Market: Vaccine Type Dashboard
4.2. Global Pneumococcal Vaccine Market: Vaccine Type Movement Analysis
4.3. Global Pneumococcal Vaccine Market by Vaccine Type, Revenue
4.4. Pneumococcal Conjugate Vaccine
4.4.1. Pneumococcal Conjugate Vaccine Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Pneumococcal Polysaccharide Vaccine
4.5.1. Pneumococcal Polysaccharide Vaccine Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Pneumococcal Vaccine Market: Product Estimates & Trend Analysis
5.1. Global Pneumococcal Vaccine Market: Product Dashboard
5.2. Global Pneumococcal Vaccine Market: Product Movement Analysis
5.3. Global Pneumococcal Vaccine Market by Product, Revenue
5.4. Prevnar 13
5.4.1. Prevnar 13 Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Synflorix
5.5.1. Synflorix Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Pneumovax 23
5.6.1. Pneumovax 23 Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. VAXNEUVANCE
5.7.1. VAXNEUVANCE Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.8. PNEUMOSIL
5.8.1. PNEUMOSIL Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.9. Other Products
5.9.1. Other Products Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Pneumococcal Vaccine Market: End Use Estimates & Trend Analysis
6.1. Global Pneumococcal Vaccine Market: End Use Dashboard
6.2. Global Pneumococcal Vaccine Market: End Use Movement Analysis
6.3. Global Pneumococcal Vaccine Market by End Use, Revenue
6.4. Public Sector
6.4.1. Public Sector Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Private Sector
6.5.1. Private Sector Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Pneumococcal Vaccine Market: Regional Estimates & Trend Analysis by Vaccine Type, Product, and End Use
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key Country Dynamics
7.3.1.2. Target Disease Prevalence
7.3.1.3. Regulatory Framework/Reimbursement Structure
7.3.1.4. Competitive Scenario
7.3.1.5. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Regulatory Framework/Reimbursement Structure
7.3.2.4. Competitive Scenario
7.3.2.5. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key Country Dynamics
7.4.1.2. Target Disease Prevalence
7.4.1.3. Regulatory Framework/Reimbursement Structure
7.4.1.4. Competitive Scenario
7.4.1.5. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework/Reimbursement Structure
7.4.2.4. Competitive Scenario
7.4.2.5. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework/Reimbursement Structure
7.4.3.4. Competitive Scenario
7.4.3.5. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework/Reimbursement Structure
7.4.4.4. Competitive Scenario
7.4.4.5. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Regulatory Framework/Reimbursement Structure
7.4.5.4. Competitive Scenario
7.4.5.5. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Regulatory Framework/Reimbursement Structure
7.4.6.4. Competitive Scenario
7.4.6.5. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Regulatory Framework/Reimbursement Structure
7.4.7.4. Competitive Scenario
7.4.7.5. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Regulatory Framework/Reimbursement Structure
7.4.8.4. Competitive Scenario
7.4.8.5. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5. Asia-Pacific
7.5.1. Japan
7.5.1.1. Key Country Dynamics
7.5.1.2. Target Disease Prevalence
7.5.1.3. Regulatory Framework/Reimbursement Structure
7.5.1.4. Competitive Scenario
7.5.1.5. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework/Reimbursement Structure
7.5.2.4. Competitive Scenario
7.5.2.5. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework/Reimbursement Structure
7.5.3.4. Competitive Scenario
7.5.3.5. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework/Reimbursement Structure
7.5.4.4. Competitive Scenario
7.5.4.5. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Regulatory Framework/Reimbursement Structure
7.5.5.4. Competitive Scenario
7.5.5.5. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Regulatory Framework/Reimbursement Structure
7.5.6.4. Competitive Scenario
7.5.6.5. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key Country Dynamics
7.6.1.2. Target Disease Prevalence
7.6.1.3. Regulatory Framework/Reimbursement Structure
7.6.1.4. Competitive Scenario
7.6.1.5. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework/Reimbursement Structure
7.6.2.4. Competitive Scenario
7.6.2.5. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework/Reimbursement Structure
7.6.3.4. Competitive Scenario
7.6.3.5. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key Country Dynamics
7.7.1.2. Target Disease Prevalence
7.7.1.3. Regulatory Framework/Reimbursement Structure
7.7.1.4. Competitive Scenario
7.7.1.5. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Regulatory Framework/Reimbursement Structure
7.7.2.4. Competitive Scenario
7.7.2.5. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Regulatory Framework/Reimbursement Structure
7.7.3.4. Competitive Scenario
7.7.3.5. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key Country Dynamics
7.7.4.2. Target Disease Prevalence
7.7.4.3. Regulatory Framework/Reimbursement Structure
7.7.4.4. Competitive Scenario
7.7.4.5. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of Key Distributors and Channel Partners
8.3.2. Key Customers
8.3.3. Key Company Market Share Analysis, 2023
8.3.4. Serum Institute of India Pvt. Ltd.
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. CSL
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Sanofi
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. GSK Plc
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Merck & Co., Inc.
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Pfizer Inc.
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Walvax Biotechnology Co., Ltd
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. Beijing Minhai Biotechnology Co.,Ltd (Subsidiary of Shenzhen Kangtai Biological Products Co. Ltd.)
8.3.11.1. Company Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America Pneumococcal Vaccine Market, 2018-2030 (USD Million)
Table 3 North America Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 4 North America Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 5 North America Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 6 U.S. Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 7 U.S. Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 8 U.S. Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 9 Canada Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 10 Canada Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 11 Canada Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 12 Europe Pneumococcal Vaccine Market, by Region, 2018-2030 (USD Million)
Table 13 Europe Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 14 Europe Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 15 Europe Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 16 Germany Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 17 Germany Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 18 Germany Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 19 UK Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 20 UK Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 21 UK Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 22 France Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 23 France Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 24 France Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 25 Italy Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 26 Italy Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 27 Italy Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 28 Spain Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 29 Spain Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 30 Spain Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 31 Denmark Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 32 Denmark Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 33 Denmark Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 34 Sweden Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 35 Sweden Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 36 Sweden Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 37 Norway Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 38 Norway Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 39 Norway Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 40 Asia-Pacific Pneumococcal Vaccine Market, by Region, 2018-2030 (USD Million)
Table 41 Asia-Pacific Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 42 Asia-Pacific Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 43 Aisa Pacific Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 44 China Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 45 China Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 46 China Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 47 Japan Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 48 Japan Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 49 Japan Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 50 India Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 51 India Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 52 India Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 53 South Korea Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 54 South Korea Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 55 South Korea Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 56 Australia Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 57 Australia Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 58 Australia Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 59 Thailand Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 60 Thailand Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 61 Thailand Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 62 Latin America Pneumococcal Vaccine Market, by Region, 2018-2030 (USD Million)
Table 63 Latin America Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 64 Latin America Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 65 Latin America Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 66 Brazil Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 67 Brazil Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 68 Brazil Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 69 Mexico Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 70 Mexico Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 71 Mexico Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 72 Argentina Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 73 Argentina Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 74 Argentina Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 75 MEA Pneumococcal Vaccine Market, by Region, 2018-2030 (USD Million)
Table 76 MEA Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 77 MEA Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 78 MEA Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 79 South Africa Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 80 South Africa Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 81 South Africa Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 82 Saudi Arabia Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 83 Saudi Arabia Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 84 Saudi Arabia Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 85 UAE Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 86 UAE Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 87 UAE Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
Table 88 Kuwait Pneumococcal Vaccine Market, by Vaccine Type, 2018-2030 (USD Million)
Table 89 Kuwait Pneumococcal Vaccine Market, by Product, 2018-2030 (USD Million)
Table 90 Kuwait Pneumococcal Vaccine Market, by End Use, 2018-2030 (USD Million)
List of Figures
Figure 1 Pneumococcal Vaccines Market Segmentation
Figure 2 Market Research Process
Figure 3 Data Triangulation Techniques
Figure 4 Primary Research Pattern
Figure 5 Value Chain Based Sizing & Forecasting
Figure 6 QFD Modelling for Market Share Assessment
Figure 7 Market Formulation & Validation
Figure 8 Market Snapshot
Figure 9 Vaccine Type and Product Segment Snapshot
Figure 10 End-use Segment Snapshot
Figure 11 Competitive Landscape Snapshot
Figure 12 Parent Market (USD Billion)
Figure 13 Market Dynamics
Figure 14 Porter’s Five Forces Analysis
Figure 15 PESTLE Analysis
Figure 16 Pneumococcal Vaccine Market: Vaccine Type Outlook and Key Takeaways
Figure 17 Pneumococcal Vaccine Market: Vaccine Type Movement Analysis
Figure 18 Pneumococcal Conjugate Vaccine (PCV) Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 19 Pneumococcal Polysaccharide Vaccine (PPV) Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 20 Pneumococcal Vaccine Market: Product Outlook and Key Takeaways
Figure 21 Pneumococcal Vaccine Market: Product Movement Analysis
Figure 22 Prevnar Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 23 Synflorix Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 24 Pneumovax 23 Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 25 VAXNEUVANCE Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 26 PNEUMOSIL Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 27 Other Products Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 28 Pneumococcal Vaccine Market: End-use Outlook and Key Takeaways
Figure 29 Pneumococcal Vaccine Market: End-use Movement Analysis
Figure 30 Public Sector Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 31 Private Sector Market Estimates and Forecast, 2018-2030 (USD Million)
Figure 32 Pneumococcal Vaccine Market Revenue, by Region, 2023 & 2030 (USD Million)
Figure 33 Regional Marketplace: Key Takeaways
Figure 34 Regional Marketplace: Key Takeaways
Figure 35 North America Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 36 Key Country Dynamics
Figure 37 U.S. Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 39 Key Country Dynamics
Figure 40 Canada Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 41 Vaccine Testing and Approval Process in Canada
Figure 42 Europe Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 43 Key Country Dynamics
Figure 44 UK Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 45 Key Country Dynamics
Figure 46 Germany Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 47 Key Country Dynamics
Figure 48 France Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 49 Key Country Dynamics
Figure 50 Spain Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 51 Key Country Dynamics
Figure 52 Italy Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 53 Key Country Dynamics
Figure 54 Denmark Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 55 Key Country Dynamics
Figure 56 Sweden Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 57 Key Country Dynamics
Figure 58 Norway Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 59 Rest of Europe Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 60 Asia-Pacific Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 61 Key Country Dynamics
Figure 62 Japan Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 63 Key Country Dynamics
Figure 64 China Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 65 China Regulatory Details
Figure 66 Key Country Dynamics
Figure 67 India Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 68 Key Country Dynamics
Figure 69 Australia Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 70 Key Country Dynamics
Figure 71 Thailand Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 72 Key Country Dynamics
Figure 73 South Korea Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 74 South Korea Reimbursement Scenario
Figure 75 Rest of Asia-Pacific Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 76 Latin America Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 77 Key Country Dynamics
Figure 78 Brazil Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 79 Brazil Regulation Details
Figure 80 Brazil Reimbursement Scenario
Figure 81 Key Country Dynamics
Figure 82 Mexico Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 84 Key Country Dynamics
Figure 85 Argentina Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 86 Argentina Regulatory Framework
Figure 87 Rest of Latin America Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 88 MEA Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 89 Key Country Dynamics
Figure 90 South Africa Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 91 Key Country Dynamics
Figure 92 Saudi Arabia Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 93 Key Country Dynamics
Figure 94 UAE Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 95 Key Country Dynamics
Figure 96 Kuwait Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)
Figure 97 Rest of MEA Pneumococcal Vaccine Market Estimates and Forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • Serum Institute of India Pvt. Ltd.
  • CSL
  • Sanofi
  • GSK plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Walvax Biotechnology Co., Ltd
  • Beijing Minhai Biotechnology Co.,Ltd (Subsidiary of Shenzhen Kangtai Biological Products Co. Ltd.)

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages125
PublishedMay 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 8.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.19 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Global Pneumococcal Vaccine Market by Type (Conjugate Vaccines, Polysaccharide Vaccines), Indication (Bronchitis, Meningitis, Pneumonia), Age Group, Distribution - Forecast 2024-2030 - Product Image

Global Pneumococcal Vaccine Market by Type (Conjugate Vaccines, Polysaccharide Vaccines), Indication (Bronchitis, Meningitis, Pneumonia), Age Group, Distribution - Forecast 2024-2030

  • Report
  • 184 Pages
  • Global
From
Pneumococcal Vaccines Market : Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

Pneumococcal Vaccines Market : Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 180 Pages
  • Global
From
Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Pneumococcal Vaccine Global Market Report 2024 - Product Image

Pneumococcal Vaccine Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Pneumococcal Vaccine Market Report and Forecast 2024-2032 - Product Image

Pneumococcal Vaccine Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.